Grifols' results evolution has served to reduce tension among investors, who have not fully calmed down since the publication of the Gotham City Research report against the Catalan company in January 2024. The share price of the plasma-derived medicines giant remains far from the levels it held before the attack, but the good performance of its accounts has been enough to question some of the most critical theses regarding its value. Among them, those of some of the short-selling investors who had accumulated positions in the company's capital, and who have been reducing or withdrawing them in recent months.

Grifols already has on the horizon the start of operations of the new production center in Lliçà de Vall (Vallès Oriental). The Catalan multinational in the plasma-derived medicines sector laid the first stone of the Vallès plant this Wednesday, which specializes in plasma fractionation and the production of derivatives. The new facilities will represent an investment of 160 million euros "in a first phase", as the company announced last summer, and will add approximately 400 new employees to the company's workforce, which already has about 4,700 employees in Spain.

The Catalan multinational pharmaceutical company Grifols will close 29 plasma donation centers in the United States, where it is the main operator with more than 300 centers. In a statement this Friday, it framed the decision within "a broader and ongoing strategy to improve long-term productivity, efficiency, and sustainability" of its network in the country.

Grifols has received certification from the European Medicines Agency (EMA) for the entire value chain of Grifols Egypt for Plasma Derivatives (GEPD), a project by the Catalan multinational specializing in plasma derivatives in partnership with the Egyptian government. The authority responsible for the scientific evaluation, supervision, and safety control of medicines in the European Union (EU) confirmed that the entire Grifols Egypt plasma platform "operates under the most demanding European standards of quality, safety, and regulatory control," the company explains. Thanks to this certification, Egypt becomes the first country in Africa and the Middle East to operate a fully integrated plasma collection and processing system "that meets the strictest international standards throughout the entire cycle, from the medical evaluation of donors and the donation process to the analysis of the medicines" and the plasma processing. This also facilitates the country's progress toward exporting surplus medicines derived from Egyptian plasma to other markets, particularly in Europe, including Spain.